
Patient-Informed Phase 2 ATLANTIS Study Tests Selective D1PAM Agent Glovadalen for Parkinson Disease
At the 2025 AD/PD International Conference on Alzheimer’s and Parkinson’s Diseases, held April 1-5 in Vienna, Austria, a poster presentation highlighted the trial design of ATLANTIS, a patient-informed phase 2 study (NCT06055985) assessing the …